Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms
Persons with myeloproliferative neoplasms (MPNs) have been well-served by translational research over the past two decades, and in the instance of chronic myeloid leukemia (CML), for the past half-century. The recent publication of the long-term results of imatinib therapy with a median follow-up of 11 years, confirms the safety and efficacy of this first-generation tyrosine kinase-inhibitor (TKI) [1,2]. Clinical progress for other subtypes of MPNs has been more limited but there have been therapy advances for certain other MPNs [3].
Source: Leukemia Research - Category: Hematology Authors: Tariq I. Mughal, Jason Gotlib, Ruben Mesa, Steffen Koschmieder, H. Jean Khoury, Jorge E. Cortes, Tiziano Barbui, R üdiger Hehlmann, Michael Mauro, Susanne Saussele, Jerald P. Radich, Richard A. Van Etten, Giuseppe Saglio, Srdnan Verstovek, Robert Peter G Source Type: research